DEF: STAAR Surgical Announces 2026 Annual Meeting Details

STAAR Surgical Company has released its proxy statement for the 2026 Annual Meeting of Shareholders, detailing director nominations, equity plan amendments, auditor ratification, and executive compensation.

Summary

• STAAR Surgical Company is holding its 2026 Annual Meeting of Shareholders virtually on June 18, 2026, at 8:30 a.m. Pacific Time.
• Shareholders of record as of April 20, 2026, are eligible to vote.
• Key proposals include the election of seven director nominees, approval of an amendment to increase shares available under the equity incentive plan, ratification of BDO USA, P.C. as the independent auditor, and an advisory vote on executive compensation.
• The company highlights recent developments including leadership changes, the termination of the Alcon merger agreement, and a cooperation agreement with Broadwood Partners.
• The letter from the Interim Co-CEOs expresses optimism for 2026, expecting renewed revenue growth and improved profitability after a period of transition in 2025.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as cautiously optimistic. While acknowledging past challenges and the need for transition, the company expresses a clear strategy and expectation for improved performance in 2026, supported by leadership changes and strategic initiatives.

Positives

• The company is holding its annual meeting to ensure shareholder engagement and governance.
• New directors have been appointed to the Board, enhancing board representation and shareholder alignment.
• The company is seeking to increase its equity incentive plan share reserve to continue attracting and retaining talent.
• The company has implemented a pay-for-performance compensation structure, with a significant portion of executive pay tied to company results.
• The company is focused on strategic imperatives for 2026, including expanding revenue, improving profitability, and accelerating innovation.

Negatives

• The company experienced a difficult year of transition in 2025, with slower revenue growth and reduced profitability.
• Macroeconomic headwinds, particularly in China, impacted business performance.
• A proposed merger with Alcon was terminated in January 2026 after shareholders voted against it.
• The company's 2024 financial results fell short of goals, leading to zero funding for the annual cash bonus plan and forfeiture of PSUs for executives.
• The company's gross burn rate increased in 2025 due to new executive hires and promotions.

Risks

• Forward-looking statements are subject to risks and uncertainties, and actual results may differ materially.
• The company's business performance has been negatively affected by macroeconomic headwinds, particularly in China.
• The termination of the Alcon merger agreement introduced temporary uncertainty.
• The company's 2025 equity awards, particularly PSUs, are subject to future vesting based on performance, which has not yet been met for fiscal 2025.
• The company's ability to continue granting equity awards at historic rates depends on shareholder approval of the equity incentive plan amendment.

Future Outlook

STAAR expects 2026 to be a stronger year, defined by renewed revenue growth, improving profitability, and continued progress across its innovation pipeline. The company is focused on expanding revenue through tighter commercial execution in priority markets and optimizing pricing and portfolio strategies. Profitability is targeted to improve through disciplined cost management and supply chain optimization. Innovation efforts will focus on product launches, pipeline visibility, and prioritizing high-impact innovations.

Management Comments

• "Less than five years ago, STAAR was experiencing a period of hyper-growth, supported by the durable advantages of our Collamer lens material and the growing global recognition that the future of refractive surgery is lens-based."
• "Across most markets, we believe refractive surgery will continue to shift toward lens-based procedures and away from laser-vision correction procedures that require corneal tissue removal."
• "In early 2025, we took decisive action to reset the business. We temporarily paused shipments to China to address elevated channel inventory, implemented significant cost reductions, and accelerated the expansion of our manufacturing capabilities in Switzerland in response to rising tariffs."
• "Today, STAAR is regaining momentum. With China inventory normalization largely complete, early demand for EVO+ TM in China exceeding expectations, meaningful cost actions behind us, and our Swiss manufacturing expansion progressing, we enter 2026 better positioned to deliver improved financial performance."
• "Our strategy is clear and grounded in three priorities: driving revenue growth through focused execution in key markets, expanding profitability through disciplined cost management and improved operating leverage, and accelerating innovation to strengthen our product portfolio and pipeline."

Industry Context

StockSavvy.ai notes that STAAR Surgical's focus on lens-based refractive surgery aligns with a broader industry trend shifting away from corneal tissue removal procedures. The company's expansion in key markets like China and the US, coupled with its innovation pipeline, positions it to capitalize on the growing demand for vision correction solutions.

Management Changes

Corporate Governance

Related Party Transactions

• Consulting agreement with director Wei Jiang for services as a special strategic advisor to the Asia Pacific business, compensated with RSUs valued at $1,275,000.
• Cooperation agreement with Broadwood Partners, L.P. (largest shareholder) and others, including reimbursement of certain fees and expenses totaling $5,036,000 to Broadwood and $962,000 to Yunqi Capital.

Stakeholder Impact

• Shareholders: The appointment of new directors and the proposed increase in equity incentive shares aim to enhance shareholder alignment and long-term value creation. The termination of the Alcon merger also directly impacts shareholders.
• Employees: Changes in leadership and the equity incentive plan are intended to motivate and retain employees. Executive compensation is tied to performance, impacting potential bonuses and equity awards.
• Management: Significant leadership changes have occurred, including the appointment of Interim Co-CEOs and the termination of the former CEO.
• Creditors: No direct impact mentioned, but improved financial performance would positively affect the company's financial health.

Next Steps

• Shareholders to vote on proposals at the 2026 Annual Meeting of Shareholders on June 18, 2026.
• Company to continue executing on its 2026 strategic imperatives: expanding revenue, improving profitability, and accelerating innovation.
• Company to conduct a global search for its next CEO.
• Company to register additional shares for the equity incentive plan upon shareholder approval.

Key Dates

Recommendation

The company is in a transition phase with significant leadership changes and the aftermath of a failed merger. While the strategic imperatives for 2026 show a positive outlook for revenue growth and profitability, the company's 2024 performance was weak, and 2025 saw considerable disruption. The success of the 2026 strategy, particularly the performance of new initiatives and the impact of macroeconomic factors, remains to be seen. Therefore, a 'hold' recommendation is appropriate pending clearer evidence of sustained operational improvement and financial recovery.

Keywords

STAAR Surgical, Proxy Statement, Annual Meeting, Director Election, Equity Incentive Plan, Executive Compensation, Corporate Governance, Auditor Ratification, Shareholder Meeting, DEF 14A